Johns Hopkins ABX Guide
Tafenoquine
INDICATIONS
FDA
FDA
- Two different brand names were FDA approved in 2018
- Krintafel™- radical cure (prevention of relapse) of Plasmodium vivax malaria in patients ≥16 years old who are receiving appropriate antimalarial therapy for acute P. vivax infection.
- Please note that tafenoquine is NOT indicated for the treatment of acute P. vivax malaria.
- Arakoda™-prophylaxis of malaria in patients ≥18 years of age
- Krintafel™- radical cure (prevention of relapse) of Plasmodium vivax malaria in patients ≥16 years old who are receiving appropriate antimalarial therapy for acute P. vivax infection.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: July 3, 2020
Citation
Avdic, Edina. "Tafenoquine." Johns Hopkins ABX Guide, The Johns Hopkins University, 2020. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540701/all/Tafenoquine.
Avdic E. Tafenoquine. Johns Hopkins ABX Guide. The Johns Hopkins University; 2020. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540701/all/Tafenoquine. Accessed July 25, 2025.
Avdic, E. (2020). Tafenoquine. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540701/all/Tafenoquine
Avdic E. Tafenoquine [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2020. [cited 2025 July 25]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540701/all/Tafenoquine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tafenoquine
ID - 540701
A1 - Avdic,Edina,Pharm.D.
Y1 - 2020/07/03/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540701/all/Tafenoquine
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
